ulcerative colitis; PREDICTORS; Biosimilar; CT-P13; Crohn’s disease; Long-term efficacy

Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn’s disease and ulcerative colitis – experiences from a single center
Background: CT-P13, the first biosimilar monoclonal antibody to infliximab (IFX), has been confirmed to be efficacious in inducing …
Klaudia Farkas, Mariann Rutka, Tamás Ferenci, Ferenc Nagy, Anita Bálint, Renáta Bor, Ágnes Milassin, Anna Fábián, Kata Judit Szántó, Zsuzsanna Végh, Zsuzsanna Kürti, Péter László Lakatos, Zoltán Szepes, Tamás Molnár
Idézet DOI URL